

Contents

Preface XXVII

Foreword: Prevention of Cancer, and the Other Degenerative Diseases of Aging, Through Nutrition XXXI

Bruce N. Ames and Joyce C. McCann

List of Contributors XXXIX

Part One General Principles 1

1 Molecular Mechanisms of Cancer Induction and Chemoprevention 3

Helmut Bartsch and Clarissa Gerhäuser

- 1.1 Cancer Chemoprevention 3
- 1.2 Molecular Mechanisms and Targets of Chemopreventive Agents 4
 - 1.2.1 Carcinogen-Blocking Activities 5
 - 1.2.2 Antimutagenic Effects and DNA Repair 5
 - 1.2.3 Targeting Epigenetic Mechanisms 6
 - 1.2.4 Radical-Scavenging and Antioxidant Effects 7
 - 1.2.5 Anti-Inflammatory Mechanisms 8
 - 1.2.6 Antitumor Promoting Activities 9
 - 1.2.7 Antiproliferative Mechanisms 11
 - 1.2.8 Induction of Apoptosis and Terminal Cell Differentiation 12
 - 1.2.9 Inhibition of Angiogenesis (Angioprevention) 13
- 1.3 Perspectives 15
- 1.4 Conclusion 16
- References 17

2 Types and Consequences of DNA Damage 21

Daniel T. Shaughnessy and David M. DeMarini

- 2.1 Introduction 21

2.2	Types of DNA Damage	22
2.3	How to Detect DNA Damage Experimentally	24
2.4	DNA Damage Response	26
2.5	Types of DNA Repair	27
2.5.1	Direct DNA Repair	27
2.5.2	Base Excision Repair	27
2.5.3	Nucleotide Excision Repair	28
2.5.4	Mismatch Repair	29
2.5.5	Homologous and Nonhomologous Recombination for Repair of Double-Strand Breaks	29
2.5.6	DNA Damage Tolerance: SOS Repair and Trans-Lesion Synthesis	30
2.6	Types of Mutations	31
2.7	Assays to Detect Mutagens	31
2.8	Implications for Chemoprevention	32
	References	32
3	Induction of DNA Damage and Cancer by Dietary Factors	35
	<i>Wolfram Parzefall, Nina Kager, and Siegfried Knasmüller</i>	
3.1	Introduction	35
3.2	Nitrosamines	35
3.3	Heterocyclic Aromatic Amines	37
3.4	Polycyclic Aromatic Hydrocarbons	40
3.5	Other Thermal Degradation Products	42
3.6	Mycotoxins	46
3.7	Carcinogens in Plant Foods	49
3.8	Food Additives and Pesticides/Herbicide Residues	49
3.9	Human Cancer Risks of Food Specific Carcinogens	50
	References	52
4	Mechanisms of Chemoprevention, Antimutagenesis, and Anticarcinogenesis: An Overview	57
	<i>Silvio De Flora, Carlo Bannicelli, Alessandra Battistella, and Maria Bagnasco</i>	
4.1	Antimutagenesis and Anticarcinogenesis	57
4.2	Strategies for Preventing Cancer and Other Mutation-Related Diseases	57
4.3	Classification of Mechanisms of Chemopreventive Agents	59
4.4	Overview of Mechanisms of Inhibitors of Mutagenesis and Carcinogenesis	60
4.4.1	Extracellular Mechanisms	60
4.4.1.1	Inhibition of Uptake	60
4.4.1.2	Inhibition of Endogenous Formation	60
4.4.1.3	Complexation, Dilution, and Deactivation	61
4.4.2	Inhibition of Genotoxic Damage and Cancer Initiation	61
4.4.2.1	Modulation of Metabolism	61

4.4.2.2	Nucleophilicity	62
4.4.2.3	Antioxidant Mechanisms	62
4.4.2.4	Inhibition of Cell Replication	62
4.4.2.5	Maintenance of DNA Structure and Modulation of its Metabolism and Repair	63
4.4.2.6	Control of Gene Expression	63
4.4.3	Inhibition of Tumor Promotion	64
4.4.3.1	Anti-Inflammatory Activity	64
4.4.3.2	Signal Transduction Modulation	64
4.4.3.3	Protection of Gap Junctional Intercellular Communications (GJIC)	64
4.4.3.4	Induction of Cell Differentiation	65
4.4.3.5	Modulation of Apoptosis	65
4.4.4	Inhibition of Tumor Progression	65
4.4.4.1	Inhibition of Angiogenesis	65
4.4.4.2	Modulation of the Hormonal Status	66
4.4.4.3	Effects on the Immune System	66
4.4.5	Inhibition of Invasion and Metastasis	66
4.5	Concluding Remarks	67
	References	68
5	Antioxidants and Cancer: Fact and Fiction	73
	<i>Andrew R. Collins and Alain Favier</i>	
5.1	Introduction	73
5.2	Fruits and Vegetables: the Evidence	73
5.3	Oxidative Damage and Antioxidants	74
5.4	Large-Scale Intervention Studies with Antioxidants	75
5.4.1	The Linxian Study	75
5.4.2	The Alpha-Tocopherol Beta-Carotene Trial in Finland	77
5.4.3	The Beta-Carotene and Retinol Efficiency Trial in the United States	77
5.4.4	The US Physicians Health Study	77
5.4.5	The MRC/BHF Heart Protection Study, United Kingdom	78
5.4.6	The SU.VI.MAX Study	78
5.4.7	Two Meta-Analyses	78
5.5	Using Surrogate Biomarkers for Disease Risk	79
5.5.1	Oxidation of Bases in DNA	79
5.5.2	Intervention Trials with Antioxidants, Using the Comet Assay to Assess DNA Damage	84
5.6	Nonantioxidant Effects of Antioxidants	87
5.7	Conclusions	87
	References	88
6	Xenobiotic Metabolism: A Target for Nutritional Chemoprevention of Cancer?	93
	<i>Hansruedi Glatt</i>	
6.1	Xenobiotics and Their Disposition – Basal Aspects	93

6.2	Classification of Biotransformation Reactions and Enzymes	95
6.2.1	Conventional Phase 1/Phase 2 Concept	95
6.2.2	Toxicological Classification of Biotransformation Reactions	98
6.2.3	Chaos and Selection	99
6.2.4	Modified Phase 1/Phase 2 Terms Used in the Chemoprevention Area	100
6.2.5	Good and Bad Enzymes	101
6.3	Toxicokinetic Interactions Leading to Enhanced or Reduced Effects of Carcinogens	102
6.3.1	Individual Known Carcinogens	102
6.3.2	Wide Sets of Identified and Unidentified Carcinogens	103
6.4	Conclusions	106
	References	107
7	Dietary Factors Regulate Metabolism of Carcinogens through Transcriptional Signaling Pathways	109
	<i>Soona Shin and Thomas W. Kensler</i>	
7.1	Introduction	109
7.2	Nrf2	110
7.2.1	Keap1-Mediated Regulation of Nrf2	112
7.2.2	Phosphorylation	113
7.2.2.1	Mitogen-Activated Protein Kinases	113
7.2.2.2	Protein Kinase C	114
7.2.2.3	CK2	114
7.3	Aryl Hydrocarbon Receptor	114
7.3.1	Regulation	115
7.4	Nuclear Receptors	116
7.4.1	Regulation of the CAR Pathway	117
7.4.2	Regulation of the PXR Pathway	117
7.5	Conclusions	118
	References	118
8	Endocrine-Related Cancers and Phytochemicals	121
	<i>Johannes C. Huber and Johannes Ott</i>	
8.1	Introduction	121
8.2	Phytoestrogens and Endocrine-Related Cancers – Epidemiological Studies	122
8.2.1	Isoflavones and Breast Cancer	122
8.2.1.1	Isoflavones and the “Window of Opportunity”	122
8.2.1.2	Serum Isoflavones and Breast Cancer	122
8.2.2	Lignans and Breast Cancer	124
8.2.3	Phytoestrogens and Prostate Cancer	125
8.3	Mechanisms of Cancer Chemoprevention by Phytoestrogens	125
8.4	Estrogen Carcinogenesis	126
8.4.1	Estrogen Metabolites and Carcinogenesis	126

8.4.2	CYP1A1	129
8.4.2.1	Polymorphisms	129
8.4.2.2	Clinical Aspects of CYP1A1 Genotypes	130
8.4.2.3	Breast and CYP1A1	131
8.4.2.4	Pharmacogenomics and Phytochemicals	132
8.4.3	CYP1B1	133
8.4.3.1	Gene and Protein Structure of CYP1B1	133
8.4.3.2	Gene Regulation	133
8.4.3.3	Epigenetic Regulation	134
8.4.3.4	Polymorphisms	134
8.4.3.5	Breast Cancer	135
8.4.3.6	Endometrial Cancer	136
8.4.3.7	Pharmacogenomics and Phytochemicals	136
8.5	Conclusion	137
	References	137
9	Inflammation-Induced Carcinogenesis and Chemoprevention	145
	<i>Hiroshi Ohshima, Susumu Tomono, Ying-Ling Lai, and Noriyuki Miyoshi</i>	
9.1	Introduction	145
9.2	Prevention of Inflammation-Associated Cancer by Avoidance of Causes of Tissue Damage	146
9.3	Chemoprevention by Modulating Inflammatory Processes	147
9.3.1	NF- κ B	147
9.3.2	iNOS	148
9.3.3	COX-2	149
9.3.4	ROS-Generating Enzymes and Antioxidant Defense Mechanisms	149
9.4	Conclusion	150
	References	151
10	DNA Methylation	153
	<i>Ian T. Johnson, Nigel J. Belshaw, and Giles O. Elliott</i>	
10.1	Introduction	153
10.2	Effects of Diet on DNA Methylation	155
10.3	Impact of Environment and Nutrition on the Human Epigenome	156
10.4	Modification of DNA Methylation by Nutrients and Phytochemicals	157
10.4.1	Folates	157
10.4.2	Selenium	158
10.4.3	Polyphenols	159
10.4.4	Isothiocyanates	160
10.5	Conclusions	160
	References	161

11	Prevention of Angiogenesis and Metastasis	163
	<i>Tariq A. Bhat, Anil Mittal, and Rana P. Singh</i>	
11.1	Introduction	163
11.2	Angiogenesis	164
11.2.1	Angiogenesis Process	165
11.2.2	Tumor Angiogenesis	166
11.2.3	Angiopreventive Agents	166
11.2.4	Lymphangiogenesis	170
11.3	Metastasis	171
11.3.1	Basic Steps in Cancer Metastasis	172
11.3.2	Epithelial–Mesenchymal Transition in Metastasis	173
11.3.3	Invasion and Migration	174
11.3.4	Homing Mechanisms	175
11.3.5	Preventive Agents for Metastasis	177
11.4	Summary	177
	References	178
12	Impact of Dietary Factors on the Immune System	183
	<i>Alexa L. Meyer</i>	
12.1	A Short Presentation of the Immune System	183
12.1.1	The First Line of Defense	183
12.1.2	Adaptive Immunity	185
12.1.3	The Immune System in Cancerogenesis	185
12.1.4	Cancer – A Serious Opponent	186
12.2	The Role of Nutrition in Immunity	186
12.2.1	Fat and Fatty Acids: Their Role in Inflammation and Beyond	186
12.2.2	Trace Elements	188
12.2.3	Vitamins	189
12.2.4	Nonnutritive Food Components	190
	References	194
13	Epidemiological Studies	199
	<i>Anthony B. Miller</i>	
13.1	Introduction	199
13.2	Observational Epidemiology Studies: What Can We Learn From Them?	200
13.3	What Are We Trying To Do with Chemoprevention?	201
13.4	How Will We Know If We Are Successful?	201
13.5	The Example of Beta-Carotene	202
13.6	Folic Acid	204
13.7	Other Micronutrients	205
13.8	Green Tea and Other Agents	206
13.9	Conclusions	207
	References	207

Part Two	Experimental Models and Methods Used in Chemoprevention Studies	209
14	Methods Used for the Detection of Antimutagens: An Overview	211
	<i>Armen Nersesyan, Miroslav Mišik, and Siegfried Knasmüller</i>	
14.1	Introduction	211
14.2	Mechanisms of DNA Protection	212
14.3	Methodological Aspects	212
14.3.1	End Points Used in Antigenotoxicity Studies	212
14.3.2	<i>In Vitro</i> Approaches	214
14.3.3	<i>In Vitro</i> Systems	215
14.3.4	Human Biomonitoring Studies	218
14.4	Limitations of the Predictive Value of Different Endpoints and Test Systems	219
14.5	Specificity of Protection	220
14.6	Dose–Effect Relationships	221
14.7	Future Trends	222
	References	222
15	Methods to Determine Total Antioxidative Capacity and Oxidative DNA Damage	229
	<i>Karl-Heinz Wagner, Miroslav Mišik, Armen Nersesyan, and Siegfried Knasmüller</i>	
15.1	Introduction	229
15.2	Methods	229
15.2.1	Trapping of Reactive Species	229
15.2.2	Approaches to Determine the Total Antioxidant Capacity	230
15.2.3	Free Radical Quenching Methods	231
15.2.4	Single-Electron Transfer Methods	234
15.3	Oxidation of Macromolecules	235
15.3.1	Biomarkers of Lipid Oxidation	235
15.3.2	Biomarkers of Protein Oxidation	238
15.4	Methods Used to Monitor Oxidative DNA Damage	239
15.4.1	<i>In Vitro</i> and <i>In Vivo</i> Approaches	240
15.5	Conclusions and Outlook	241
	References	241
16	Measurement of Enzymes of Xenobiotic Metabolism in Chemoprevention Research	245
	<i>Wolfgang W. Huber and Michael Grusch</i>	
16.1	Introduction	245
16.2	Important Enzymes of Xenobiotic Metabolism in Cancer Chemoprevention Research	246
16.3	Measurement of Xenobiotic Metabolism: General Aspects	247

16.3.1	Determination of Enzyme Encoding genes (Investigation at DNA Level)	249
16.3.2	Determination of Enzyme Transcription (Investigation at RNA Level)	249
16.3.3	Determination of Enzyme Protein	250
16.3.3.1	Measurement of Enzyme Activity: General Aspects	252
16.3.3.2	Activity Measurements in Humans	255
16.4	Summary	255
	References	256
17	Methods for the Analysis of DNA Methylation	263
	<i>Keith N. Rand and Peter L. Molloy</i>	
17.1	Introduction	263
17.2	Measurement of Global and Repeat Sequence Methylation	264
17.3	Measurement of Methylation of Individual Genes or Regions	267
17.3.1	Methylation Sensitive PCR	269
17.3.2	Non-Bisulfite-Based Assay	270
17.4	Scanning Genome-Wide for Changes in DNA Methylation	270
	References	273
18	Methods Used to Study Alterations of Cell Signaling and Proliferation	277
	<i>Clarissa Gerhäuser</i>	
18.1	Introduction	277
18.2	Methods to Detect Alterations in Cell Signaling	278
18.2.1	Initializing Events	278
18.2.2	Signal Transduction to Intracellular Targets	280
18.2.2.1	Detection Using Phosphospecific Antibodies	280
18.2.2.2	Kinase Assay After Immunoprecipitation	281
18.2.3	Transcription Factor Activation	281
18.2.3.1	Transcription Factor–DNA Binding	281
18.2.3.2	Promoter Assays After Transfection with Reporter Gene Constructs	281
18.2.4	Gene Transcription and Translation	282
18.3	Methods to Measure Cell Proliferation	282
18.3.1	Microplate Screening Assays for Cytotoxicity	282
18.3.2	Cell Cycle Analysis [20]	282
18.3.3	Cell Death: Induction of Apoptosis	286
18.3.3.1	Methods to Detect Induction of Apoptosis	286
	References	287
19	Methods for the Assessment of Antiangiogenic Activity	291
	<i>Clarissa Gerhäuser</i>	
19.1	Introduction	291

19.2	Methods for Assaying Angiogenesis	291
19.2.1	<i>In vitro</i> Test Systems	292
19.2.1.1	Cell-Based Systems	292
19.2.1.2	Organ Culture Systems	295
19.2.2	<i>In vivo</i> Models	296
19.3	Conclusions	299
	References	300
20	Nutrigenomics	303
	<i>Jan Frank and Gerald Rimbach</i>	
20.1	Defining the “-omics”	303
20.2	Post-Transcriptional Gene Regulation by Small RNAs	305
20.3	Methods and Techniques Used in Nutrigenomic Research	306
20.3.1	Northern Blotting	306
20.3.2	Reverse Transcription Polymerase Chain Reaction	306
20.3.3	Microarrays	307
20.3.4	Microarray Data Normalization	310
20.3.4.1	Per Array Normalization	310
20.3.4.2	Per Gene Normalization	310
20.3.5	Microarray Data Analysis	311
20.3.5.1	Fold Change	311
20.3.5.2	Class Comparison, Class Discovery, and Class Prediction	313
20.4	Applications of Nutrigenomics	314
20.5	Proteomics	319
20.6	Metabolomics	320
20.7	Promoting Nutrigenomic Research	322
20.8	Summary	322
	References	323
21	Preneoplastic Models and Carcinogenicity Studies with Rodents	335
	<i>Veronika A. Ehrlich and Siegfried Knasmüller</i>	
21.1	Introduction	335
21.2	Animal Models Based on the Use of Carcinogens	335
21.2.1	Use of Preneoplastic Lesions in Experimental Oncology	335
21.2.1.1	Altered Hepatic Foci (AHF) – Morphology and Phenotypes	337
21.2.1.1.1	Methodical Aspects	338
21.2.1.1.2	Initiators and Promoters of AHF	339
21.2.1.1.3	Mechanistic Aspects to the Action of Promoters	339
21.2.1.1.4	Inhibition of Foci Formation in the Liver	339
21.2.1.1.5	New Developments	340
21.2.1.2	Aberrant Crypts in the Colon	340
21.2.1.2.1	Morphology	340
21.2.1.2.2	Biochemical and Immunohistochemical Alterations of ACF	341
21.2.1.2.3	Genetic and Epigenetic Alterations	341
21.2.1.2.4	Methodological Aspects	341

21.2.1.2.5	Use of the ACF Model for the Detection of Chemoprotective Compounds	343
21.2.1.2.6	New Developments	346
21.3	Genetically Engineered Rodent Models Used in Cancer Prevention Studies	346
21.3.1	Intestinal Cancers in Transgenic Apc ^{Min/+} Mouse Model	347
21.3.2	Germline p53-Deficient and p53 Mutated Animals	347
21.3.3	Rodent Models of Prostate Cancer	347
21.3.4	Other Transgenic Models	349
21.4	Xenograft Models	349
21.5	Conclusions	350
	References	351
22	The Role of Nutrition in the Etiology of Human Cancer: Methodological Considerations Concerning Epidemiological Studies	357
	<i>Heiner Boeing</i>	
22.1	Introduction	357
22.2	Principles for Evaluating the Link between Nutrition and Cancer	358
22.2.1	Intervention Studies	358
22.2.2	Prospective Cohort Studies	359
22.2.3	Case-Control and Other Studies	359
22.3	Methodological Statistical Challenges Regarding Dietary Assessment	360
22.4	Complexity of Dietary Data and Their Analyses	361
22.5	Current Status of the Evidence	362
22.5.1	Fruit and Vegetables	362
22.5.2	Meat and Meat Products	363
22.5.3	Grains	364
22.5.4	Lipids (Fat)	364
22.5.5	Use of Alcoholic Beverages	364
22.6	Summary and Conclusion	365
	References	365

Part Three Selected Chemoprotective Dietary Factors and Components 369

23	Carotenoids and Vitamin A	371
	<i>M. Cristina Polidori and Wilhelm Stahl</i>	
23.1	Introduction	371
23.2	Carotenoids – Biochemical Properties	374
23.3	β-Carotene – Cancer Prevention	376
23.4	Lycopene – Cancer Prevention	377
23.5	Other Carotenoids – Cancer Prevention	378
23.6	Retinoids – Biological Properties	378

23.7	Retinoids – Cancer Prevention	380
	References	382
24	Selected Vitamins	385
24.1	Vitamin C	385
	<i>Pavel Kramata and Nanjoo Suh</i>	
24.1.1	Introduction	385
24.1.2	Physicochemical Properties	386
24.1.3	Bioavailability and Metabolism	387
24.1.4	Mechanism of Protection: <i>In Vitro</i> and <i>In Vivo</i> Studies	388
24.1.4.1	Vitamin C and Oxidative DNA Damage	389
24.1.4.2	Vitamin C, Cell Proliferation, Signal Transduction, and Apoptosis	389
24.1.5	Human Studies	390
24.1.5.1	Epidemiological Studies	390
24.1.5.2	Clinical Studies	391
24.1.6	Impact of Cooking and Food Processing on Protective Properties	392
24.2	Vitamin D	393
	<i>Heide S. Cross and Thomas Nittke</i>	
24.2.1	Introduction	393
24.2.1.1	How Much Vitamin D is Enough?	393
24.2.2	Vitamin D Synthesis	394
24.2.3	Bioavailability and Metabolism of 1,25-(OH) ₂ -D ₃	394
24.2.4	Mechanisms of Protection	395
24.2.4.1	Vitamin D Signaling Pathways in Cancer	395
24.2.5	<i>In Vivo</i> Studies with 1,25-D ₃ for Tumor Prevention or Treatment	397
24.2.5.1	Treatment	397
24.2.5.2	Tumor Prevention	399
24.2.6	Impact of Processing on Vitamin D in Human Nutrition and Conclusion	402
24.3	Vitamin E	402
	<i>Hong Jin Lee and Nanjoo Suh</i>	
24.3.1	Introduction	402
24.3.2	Physicochemical Properties of Vitamin E, Chemical Structures, and Chemical Reactions	403
24.3.2.1	Structure of Vitamin E Components	403
24.3.2.2	Vitamin E in Human Diet	403
24.3.3	Bioavailability and Metabolism of Vitamin E	404
24.3.3.1	Bioavailability and Biopotency of Vitamin E	404
24.3.3.2	Metabolism of Vitamin E	404
24.3.4	<i>In Vitro</i> and Animal Studies of Vitamin E	406
24.3.4.1	Mechanism of Antioxidant Protection	406
24.3.4.2	Nonantioxidant Functions of Vitamin E	407
24.3.4.3	Anticancer Mechanisms of Vitamin E Action	407

24.3.4.4	Vitamin E and Preclinical Studies	407
24.3.5	Vitamin E and Human Intervention Trials	408
24.3.6	Impact of Cooking, Processing, and Other Factors on Protective Properties of Vitamin E	409
	References	409
25	Folate and Vitamins B2, B6, and B12	417
	<i>Philip Thomas and Michael Fenech</i>	
25.1	Introduction	417
25.2	Physicochemical and Transport Properties	418
25.3	Bioavailability and Metabolism of Active Compounds	420
25.3.1	Bioavailability	420
25.3.2	Metabolism	422
25.4	Mechanisms of Protection – <i>In Vitro</i> Studies	423
25.5	Results from Human Studies	424
25.6	Impact of Cooking, Processing, and Other Factors on Protective Properties	429
25.7	Conclusions	430
	References	430
26	Micronutrients and Susceptibility to Cancer: Focus on Selenium and Zinc	435
	<i>Dianne Ford and John Hesketh</i>	
26.1	Introduction	435
26.2	Selenium and Zinc in Food	435
26.3	Mechanisms of Chemoprevention by Selenium: Results of <i>In Vitro</i> and Animal Studies	436
26.4	Results from Human Studies of the Influence of Selenium Status on Cancer Risk	438
26.4.1	Genetic Influences on Selenium Metabolism and Disease Risk	440
26.5	Mechanisms of Chemoprevention by Zinc: Results of <i>In Vitro</i> and Animal Studies	441
26.5.1	Zinc as an Antioxidant	442
26.5.2	Effects of Zinc on Cell Proliferation and Apoptosis	443
26.5.3	Effects of Zinc on Cell Motility and Invasion	444
26.5.4	Effects of Zinc on Intermediary Metabolism	444
26.5.5	Intracellular Zinc Signaling in Cancer	444
26.5.6	Zinc Transporters and Cancer	445
26.5.7	Effects of Dietary Zinc Manipulation on Cancer Incidence and Progression in Animal Models	445
26.6	Human Studies of Links between Zinc, Carcinogenesis, and Tumor Progression	446
26.6.1	Associations Between Zinc Status and Cancer Incidence and Progression	446

26.6.2	Effects of Dietary Zinc Manipulation on Cancer Incidence and Progression <i>In Vivo</i>	447
26.7	Conclusions	448
	References	449
27	DNA Damage and Cancer Chemoprevention by Polyphenols	455
	<i>Ajaikumar B. Kunnumakkara, Preetha Anand, Kuzhuvilil B. Harikumar, and Bharat B. Aggarwal</i>	
27.1	Introduction	455
27.2	Physical–Chemical Properties of Polyphenols and Their Occurrence	455
27.3	Mechanisms of Chemoprevention by Phenolic Compounds: Results of <i>In Vitro</i> Studies	460
27.3.1	Polyphenols Protect Against Chemical-Induced DNA Damage	460
27.3.2	Polyphenols Protect Against Radiation-Induced DNA Damage	464
27.4	Mechanisms of Chemoprevention by Phenolic Compounds: Results of <i>In Vivo</i> Studies	465
27.4.1	Polyphenols Prevent Colon, Esophagus, and Gastric Cancer	465
27.4.2	Polyphenols Prevent Ascites Tumor	468
27.4.3	Polyphenols Inhibit Breast Cancer	468
27.4.4	Polyphenols Inhibit Liver Cancer	469
27.4.5	Polyphenols Inhibit Neuroblastoma and Glioma	470
27.4.6	Polyphenols Inhibit Leukemia	470
27.4.7	Polyphenols Inhibit Prostate Cancer	471
27.4.8	Polyphenols Inhibit Skin Cancer	472
27.4.9	Polyphenols Inhibit Lung Cancer	473
27.4.10	Polyphenols Inhibit Bladder Cancer	474
27.4.11	Polyphenols Inhibit Oral Cancer	474
27.5	Mechanisms of Chemoprevention by Phenolic Compounds: Results of Human Studies	475
27.6	Effects of Food Processing on Chemoprotective Properties of Polyphenols	476
27.7	Conclusion	476
	References	477
28	Antioxidant, Anti-inflammatory, and Anticarcinogenic Effects of Ginger and Its Ingredients	483
	<i>Hye-Kyung Na, Joydeb Kumar Kundu, and Young-Joon Surh</i>	
28.1	Introduction	483
28.2	Antioxidant Effects	483
28.3	Anti-Inflammatory Effects	485
28.4	Anticarcinogenic Effects	488
28.4.1	Inhibition of Mouse Skin Carcinogenesis	488
28.4.2	Inhibition of Gastric Lesions and Tumorigenesis	489
28.4.3	Inhibition of Bladder Carcinogenesis	490

28.4.4	Inhibition of Tumor Cell Growth and Proliferation	490
28.4.5	Antimetastasis and Antiangiogenesis	492
28.4.6	Effects on Multidrug Resistance	492
28.5	Chemoprotective Effects	493
28.6	Conclusion	493
	References	494
29	Tannins: Bioavailability and Mechanisms of Action	499
	<i>Fulgencio Saura-Calixto and Jara Pérez-Jiménez</i>	
29.1	Introduction	499
29.2	Physicochemical Properties	500
29.3	Bioavailability and Metabolism	501
29.3.1	Proanthocyanidins	501
29.3.2	Hydrolyzable Tannins	502
29.4	Mechanisms of Protection	503
29.5	Results of Human Studies	505
29.6	Impact of Cooking and Processing	506
	References	506
30	Selected Flavonoids	509
30.1	Quercetin and other Flavonols	509
	<i>Loïc Le Marchand and Adrian A. Franke</i>	
30.1.1	Introduction	509
30.1.2	Physicochemical Properties of Active Compounds and their Occurrence	509
30.1.3	Bioavailability and Metabolisms of Active Compounds	512
30.1.4	Mechanisms of Protection	514
30.1.5	Results of Human Studies	514
30.1.5.1	Cohort Studies	515
30.1.5.2	Case–Control Studies	515
30.1.6	Impact of Storage, Processing, and Cooking on Protective Properties	515
30.1.7	Research Needs	516
30.2	Anthocyanidins	516
	<i>Li-Shu Wang and Gary D. Stoner</i>	
30.2.1	Introduction	516
30.2.2	Physicochemical Properties of Anthocyanidins	517
30.2.3	Bioavailability and Metabolism of Anthocyanins	518
30.2.4	Mechanisms of Chemoprotection by Anthocyanidins and Anthocyanins	518
30.2.4.1	<i>In Vitro</i> Studies	518
30.2.4.2	Animal Studies	522
30.2.5	Human Studies	523
30.2.6	Impact of Processing on the Stability of Anthocyanins	524
30.2.7	Conclusions	524

30.3	Proanthocyanidins 525 <i>Clarissa Gerhäuser</i>
30.3.1	Introduction 525
30.3.2	Physicochemical Properties and Occurrence 525
30.3.2.1	Physicochemical Properties 525
30.3.2.1.1	Interaction with Proteins 525
30.3.2.1.2	Antioxidant and Radical Scavenging Capacity 527
30.3.2.1.3	Complexation of Metal Ions 527
30.3.2.2	Occurrence 527
30.3.3	Bioavailability and Metabolisms [97–99,104–107] 528
30.3.4	Mechanisms of Protection: Results of <i>In Vitro</i> and Animal Studies 529
30.3.4.1	<i>In vitro</i> Antioxidant Activity 529
30.3.4.2	Potential Cancer Chemopreventive Activity in Cell Culture 529
30.3.4.3	Cancer Chemopreventive Activity in Animal Models 534
30.3.5	Results of Human Studies 534
30.3.5.1	Short-Term Intervention Studies 534
30.3.5.2	Epidemiological Studies 537
30.3.6	Impact of Cooking, Processing, and other Factors on Protective Properties 537
30.3.7	Conclusions 538 References 538
31	Phytoestrogens 547
31.1	Isoflavones: Sources, Intake, Fate in the Human Body, and Effects on Cancer 547 <i>Alicja Mortensen, Sabine Kulling, Heidi Schwartz, and Gerhard Sontag</i>
31.1.1	Introduction 547
31.1.2	Dietary Isoflavone Sources 547
31.1.3	Dietary Intake of Isoflavones 548
31.1.4	Absorption, Distribution, Metabolism, and Excretion of Isoflavones 549
31.1.4.1	Absorption 549
31.1.4.2	Metabolism 550
31.1.4.3	Distribution 551
31.1.4.4	Excretion 552
31.1.4.5	Pharmacokinetics 552
31.1.4.6	Factors Affecting the Pharmacokinetics of Isoflavones 552
31.1.5	Effects of Isoflavones on Breast, Prostate, and Intestinal Cancer 553
31.1.5.1	Breast Cancer 553
31.1.5.2	Prostate Cancer 554
31.1.5.3	Intestinal Cancer 554
31.2	Lignans 555 <i>Eric Lainé, Christophe Hano, and Frédéric Lamblin</i>
31.2.1	Introduction 555
31.2.2	Occurrence and Physicochemical Properties 556

- 31.2.2.1 Phytoestrogenic Nature 558
- 31.2.2.2 Antioxidant Properties 560
- 31.2.3 Bioavailability 561
- 31.2.4 Mechanisms of Protection: Results of In Vitro and Animal Studies 562
 - 31.2.4.1 Inhibition of Tumorigenesis 562
 - 31.2.4.2 Inhibition of Metastasis 562
 - 31.2.4.3 Other Less Documented Mechanisms 562
- 31.2.5 Results of Human Studies 565
 - 31.2.5.1 Breast Cancer 566
 - 31.2.5.2 Prostate Cancer 567
 - 31.2.5.3 Colon Cancer 567
- 31.2.6 Impact of Cooking, Processing, and Other Factors on Protective Properties 567
- 31.2.7 Conclusions 568
- References 568

- 32 Chemopreventive Properties of Coffee and Its Constituents 579**
Gernot Faustmann, Christophe Cavin, Armen Nersesyan, and Siegfried Knasmüller
 - 32.1 Introduction 579
 - 32.2 Bioactive Components in Coffee 580
 - 32.3 Mechanisms of Chemoprevention 580
 - 32.3.1 Protective Properties of Coffee 581
 - 32.3.1.1 Antioxidant Effects 581
 - 32.3.1.2 Induction of Detoxifying Enzymes 583
 - 32.3.2 Protective Properties of Coffee Components 583
 - 32.3.2.1 Antioxidant Effects 583
 - 32.3.2.2 Induction of Detoxifying Enzymes 585
 - 32.3.2.3 Protective Effects of Coffee Constituents Toward Genotoxic Carcinogens 585
 - 32.3.2.4 Interaction of Coffee and Coffee Diterpenes with Cell Signaling Pathways 587
 - 32.4 Coffee Consumption and Human Cancer Risks 588
 - 32.5 Concluding Remarks 590
 - References 590

- 33 Tea and Its Constituents 595**
 - 33.1 Green Tea and Its Constituents: Protection Against DNA Damage and Carcinogenesis 595
Joshua D. Lambert and Chung S. Yang
 - 33.1.1 Introduction 595
 - 33.1.2 Bioavailability and Biotransformation of Tea Polyphenols 596
 - 33.1.2.1 Biotransformation of Tea Polyphenols 596
 - 33.1.2.2 Pharmacokinetics of Tea Polyphenols 598
 - 33.1.3 *In Vitro* and Animal Studies of Cancer Prevention by Tea 599

33.1.3.1	Antioxidative/Pro-Oxidative Activities	599
33.1.3.2	Effects on Carcinogen Metabolism	600
33.1.3.3	Prevention and Repair of DNA Damage	601
33.1.3.4	Prevention of Carcinogenesis and Potential Postinitiation Mechanisms	602
33.1.4	Studies on the Cancer-Preventive Activity of Tea in Humans	604
33.1.4.1	Antioxidative Activity	604
33.1.4.2	Effects on Carcinogen Metabolism	604
33.1.4.3	Prevention and Repair of DNA Damage	604
33.1.4.4	Epidemiological and Intervention Studies on Cancer Prevention by Tea	605
33.1.5	Impact of Cooking, Processing, and Other Factors on Protective Effects	607
33.1.6	Concluding Remarks	608
33.2	Black and Other Teas	609
	<i>Wentzel C.A. Gelderblom, Kareemah Gamielien, and Elizabeth Joubert</i>	
33.2.1	Introduction	609
33.2.2	Physicochemical Properties of Active Compounds and their Occurrence	610
33.2.2.1	Black Tea	610
33.2.2.2	Rooibos Tea	610
33.2.2.3	Honeybush Tea	613
33.2.3	Bioavailability and Metabolism of Active Compounds	615
33.2.4	Mechanisms of Protection: Results of <i>In Vitro</i> and Animal Studies	616
33.2.4.1	Antimutagenic Properties	616
33.2.4.2	Antioxidant Properties	617
33.2.4.3	Studies in Animals	619
33.2.4.4	Cell Survival Parameters	620
33.2.5	Results of Human Studies	621
33.2.6	Impact of Heat and Processing on Protective Properties	622
33.2.6.1	Black Tea	622
33.2.6.2	Rooibos and Honeybush	622
33.2.7	Concluding Remarks	623
	References	623
34	Protective Effects of Alcoholic Beverages and their Constituent	635
34.1	Wine	635
	<i>Philipp Saiko, Akos Szakmary, and Thomas Szekeres</i>	
34.1.1	Introduction	635
34.1.1.1	General Information and Historical Background	635
34.1.1.2	The Health Effects of Wine	636
34.1.1.3	Ingredients of Wine	636
34.1.2	Physicochemical Properties of Active Compounds, Occurrences, and Chemical Structures	637

34.1.2.1	Resveratrol	637
34.1.2.1.1	History and Sources	637
34.1.2.1.2	French Paradox	638
34.1.2.1.3	Effects of Resveratrol	638
34.1.2.2	Piceatannol: A Naturally Occurring Resveratrol Metabolite	640
34.1.2.3	Gallic Acid	640
34.1.3	Bioavailability and Metabolism of Active Compounds	642
34.1.3.1	Bioavailability of Resveratrol	642
34.1.3.2	Metabolites of Resveratrol: Glucuronide and Sulfate Conjugates	642
34.1.3.3	Bioavailability of Resveratrol in Grape Juice Compared to Its Pure Aglycone	642
34.1.4	Mechanisms of Protection	643
34.1.4.1	Results of <i>In Vitro</i> Studies	643
34.1.4.2	Results of <i>In Vivo</i> Studies	643
34.1.5	Results of Human Studies	643
34.1.6	Conclusions	643
34.2	Beer	648
	<i>Metka Filipic, Janja Plazar, and Sakae Arimoto-Kobayashi</i>	648
34.2.1	Introduction	648
34.2.2	Physicochemical Properties of Bioactive Compounds	649
34.2.2.1	Prenylated Flavonoids	649
34.2.2.2	Bitter Acids	650
34.2.2.3	Nitrogenous Compounds	651
34.2.3	Mechanisms of Chemoprevention: Results <i>In Vitro</i> and <i>In Vivo</i>	652
34.2.3.1	Prenylated Flavonoids	652
34.2.3.2	Bitter Acids	653
34.2.3.3	Nitrogenous Compounds and other Unidentified Components	653
34.2.4	Results of Human Studies	655
34.2.5	Effect of Beer Processing on Chemoprotective Properties	656
	References	656
35	Sulfides in <i>Allium</i> Vegetables	663
	<i>Claus Jacob and Awais Anwar</i>	
35.1	Introduction	663
35.2	Physicochemical Properties	665
35.3	Bioavailability and Metabolisms of Active Compounds	667
35.3.1	Enzymatic Generation of Reactive Sulfur Species as Part of Binary Plant Defense Systems	667
35.3.2	Follow-On Products Formed by Degradation of Reactions with Biomolecules	669
35.3.3	Chemical Recycling of Allicin	670

35.4	Mechanisms of Protection	671
35.4.1	Sulfur-based Scavengers of Free Radicals and Other Oxidative Stressors	671
35.4.2	Prevention of Carcinogen Activation by Inhibition of Metabolic (Phase I) Enzymes	673
35.4.3	Induction of Phase II Enzymes	673
35.4.4	Sulfur Agents as HDAC Inhibitors	674
35.4.5	Interference with Cancer Promoting, Cell Signaling Pathways	674
35.4.6	Cell Cycle Arrest and Induction of Apoptosis	675
35.4.7	Sulfur Agents and Angiogenesis	676
35.4.8	Counteracting Multidrug Resistance	677
35.5	Results of Human Studies	677
35.6	Impact of Cooking, Processing, and Other Factors on Protective Properties	678
35.7	Outlook	680
35.8	Conclusion	681
	References	681
36	Glucosinolates and Cruciferous Vegetables	685
	<i>L. Adele Boyd, Cris Gill, Tomas Borkowski, and Ian Rowland</i>	
36.1	Introduction	685
36.1.1	Cruciferous Vegetables and Their Components	685
36.1.2	Physicochemical Properties of Phytochemicals in Cruciferous Vegetables	685
36.2	Bioavailability and Metabolisms of Active Compounds	686
36.2.1	Gastric and Small-Intestinal Breakdown	689
36.2.2	Colonic Metabolism	689
36.2.3	Absorption from the Gut	689
36.2.4	Metabolism and Excretion of Hydrolysis Products	689
36.3	Mechanisms of Protection: Results of <i>In Vitro</i> and <i>Animal Studies</i>	690
36.3.1	Animal Studies	690
36.3.2	Effects of Vegetable Extracts and Components at the Cellular and Molecular Level	691
36.4	Human Studies	692
36.4.1	Epidemiology	692
36.4.2	Dietary Intervention Studies	692
36.4.2.1	Effects on Phase I and Phase II Enzyme Activities and Carcinogen Excretion in Humans	693
36.4.2.2	Antigenotoxic Effects of Cruciferous Vegetables	694
36.5	Impact of Cooking and Processing	695
36.5.1	Storage and Processing	695
36.5.2	Cooking	695
36.5.3	Consequences for Bioavailability	695

36.6	Conclusions	696
	References	696
37	Chlorophyll	699
	<i>Hikoya Hayatsu, Tomoe Negishi, and Sakae Arimoto-Kobayashi</i>	
37.1	Introduction	699
37.2	Chemical Nature of Chlorophylls	699
37.3	Historical Background	701
37.4	Basic Studies on Antigenotoxic Activities of Chlorophylls and the Mechanism of the Actions	701
37.5	Chlorophyll–Carcinogen Complex Formation	702
37.6	Studies with Higher Organisms	704
37.7	Studies with Human Subjects	705
	References	706
38	Dietary Fibers	709
	<i>Philip J. Harris and Lynnette R. Ferguson</i>	
38.1	Introduction	709
38.2	Physicochemical Properties of Active Compounds and Their Occurrence	711
38.3	Bioavailability and Metabolism of Active Compounds	712
38.4	Mechanisms of Chemoprevention: Results of <i>In Vitro</i> and Animal Studies	712
38.4.1	Lignified or Suberized Cell Walls	713
38.4.2	Cell Walls Containing Hydroxycinnamic Acids	714
38.5	Results of Human Studies	715
38.6	Impact of Cooking, Processing, and Other Factors on Protective Properties	716
38.7	Conclusions	716
	References	717
39	Dietary Fiber Carbohydrates and their Fermentation Products	721
	<i>Lynnette R. Ferguson and Philip J. Harris</i>	
39.1	Introduction	721
39.2	Physicochemical Properties of Active Compounds and their Occurrence	721
39.3	Bioavailability and Metabolism of Active Compounds	724
39.4	Mechanisms of Chemoprevention: Results of <i>In Vitro</i> and Animal Studies	724
39.4.1	Hypotheses Suggesting that SCFAs are Protective	724
39.4.2	The Butyrate Hypothesis	724
39.4.3	Prebiotic Effects	725
39.4.4	Evidence from Animal Models	725
39.5	Results of Human Studies	726

39.6	Impact of Cooking, Processing, and other Factors on Protective Properties	726
39.7	Conclusions	727
	References	727
40	Lactobacilli and Fermented Foods	731
	<i>Sabine Fuchs, Reinhard Stidl, Verena Koller, Gerhard Sontag, Armen Nersesyan, and Siegfried Knasmüller</i>	
40.1	Introduction	731
40.2	Occurrence of Lactic Acid Bacteria	733
40.3	Detoxification of Genotoxic Carcinogens by Lactic Acid Bacteria	733
40.4	Antioxidant Effects of Lactic Acid Bacteria	737
40.5	Effect of Lactic Acid Bacteria on the Immune Status	739
40.6	Results of Carcinogenicity Studies with Laboratory Rodents	740
40.7	Impact of Lactic Acid Bacteria on Cell Proliferation and Apoptosis	742
40.8	Results of Human Epidemiological Studies	742
40.9	Conclusions and Future Research	743
	References	743
41	Fatty Acids and Cancer Prevention	749
	<i>Elizabeth K. Lund</i>	<i>749</i>
41.1	Introduction	749
41.2	Fatty Acid Structure	750
41.3	Bioavailability	751
41.4	Epidemiology	752
41.5	Animal Models	753
41.6	<i>In Vitro</i> Studies	754
41.7	Mechanisms of Action	754
41.8	Conclusion	757
	References	757
42	Protease Inhibitors	761
	<i>Ann R. Kennedy</i>	
42.1	Introduction	761
42.2	Physicochemical Properties of Active Compounds and Their Occurrence	761
42.3	Bioavailability and Metabolism of Active Compounds	762
42.4	Mechanisms of Protection and Results of <i>In Vitro</i> and Animal Studies	762
42.5	Results of Human Studies	764
42.6	Impact of Cooking Processing	766
	References	766
	Index	769

